Literature DB >> 29555533

Long-term results of CT-guided percutaneous radiofrequency ablation of inoperable patients with stage Ia non-small cell lung cancer: A retrospective cohort study.

Bing-Yang Huang1, Xin-Min Li2, Xiao-Yong Song1, Jun-Jun Zhou1, Zhuang Shao1, Zhi-Qi Yu1, Yi Lin1, Xin-Yu Guo1, Da-Jiang Liu1, Lu Li3.   

Abstract

BACKGROUND: This study was performed to retrospectively evaluate the 10-year overall survival (OS), progression-free survival (PFS), and local control rates of patients with inoperable stage Ia non-small cell lung cancer (NSCLC) who underwent computed tomography (CT)-guided radiofrequency ablation (RFA) in a single center.
MATERIALS AND METHODS: Fifty patients with inoperable NSCLC underwent RFA between 2004 and 2016. Thoracic surgeons evaluated the patients and performed RFA under CT guidance. Follow-up CT and positron emission tomography/CT scans were obtained. Local control rates and recurrence patterns were analyzed.
RESULTS: Seventy-three lesions in 50 patients (M:F = 22:28; median age: 73 years; range: 52-82 years) were treated with CT-guided RFA. The mean lesion size was 2.2 cm (range: 1-3 cm). No procedure-related deaths occurred. Low-grade fever was the most common post-ablation complication, with an incidence rate of 36%. The 1-, 2-, 3-, 5-, and 10-year OS rates of patients with Ia NSCLC were 96.0%, 86.5%, 67.1%, 36.3%, and 1%, respectively, and the 1-, 2-, 3-, and 5-year PFS rates were 94.0%, 77.5%, 43.5%, and 10.8%, respectively. The most common pattern of recurrence was local, and 15 patients with recurrence were treated with repeat RFA. Tumor size <2.0 cm was associated with a significantly improved 3-year survival rate of 78.9%.
CONCLUSION: CT-guided RFA is feasible and well tolerated by inoperable patients with inoperable stage Ia NSCLC.
Copyright © 2018 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ia non-small cell lung cancer; Minimally invasive treatment; Radiofrequency ablation

Mesh:

Year:  2018        PMID: 29555533     DOI: 10.1016/j.ijsu.2018.03.034

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  8 in total

1.  The TGF-β/Smad Pathway Inhibitor SB431542 Enhances The Antitumor Effect Of Radiofrequency Ablation On Bladder Cancer Cells.

Authors:  Hong-Qing Zhou; Ming-Sheng Liu; Ti-Bin Deng; Ping-Bo Xie; Wei Wang; Tao Shao; Yao Wu; Peng Zhang
Journal:  Onco Targets Ther       Date:  2019-09-23       Impact factor: 4.147

2.  Computed Tomography-Guided Percutaneous Radiofrequency Ablation in Older Adults With Early-Stage Peripheral Lung Cancer: A Retrospective Cohort Study.

Authors:  Yanda Lu; Caiwei Lu; Danni Xu; Fen Huang; Zhihui He; Junhua Lei; Huamao Sun; Jiangzheng Zeng
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

3.  Clinical Outcome of CT-Guided Stereotactic Ablative Brachytherapy for Unresectable Early Non-Small Cell Lung Cancer: A Retrospective, Multicenter Study.

Authors:  Zhe Ji; Bin Huo; Shifeng Liu; Qinghua Liang; Chao Xing; Miaomiao Hu; Yanli Ma; Zhe Wang; Xinxin Zhao; Yuqing Song; Yufeng Wang; Hongmei Han; Kaixian Zhang; Ruoyu Wang; Shude Chai; Xuequan Huang; Xiaokun Hu; Junjie Wang
Journal:  Front Oncol       Date:  2021-09-15       Impact factor: 6.244

4.  Local ablation of pulmonary malignancies abutting pleura: Evaluation of midterm local efficacy and safety.

Authors:  Hong-Tao Hu; Xiao-Hui Zhao; Chen-Yang Guo; Quan-Jun Yao; Xiang Geng; Wen-Bo Zhu; Hong-Le Li; Wei-Jun Fan; Hai-Liang Li
Journal:  Front Oncol       Date:  2022-08-22       Impact factor: 5.738

5.  Percutaneous local tumor ablation vs. stereotactic body radiotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Dongjie Chen; Man Zhao; Xiaoyong Xiang; Jun Liang
Journal:  Chin Med J (Engl)       Date:  2022-07-14       Impact factor: 6.133

6.  Ablation Therapy Combined with EGFR TKIs in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Lu-Zhen Li; Jia-Ming Wu; Ting Chen; Liang-Chen Zhao; Juan-Na Zhuang; Hui-Si Hong; Ao Zhang; Hua-Tang Zhang; Can-Tu Fang
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-07       Impact factor: 2.629

7.  Assessment of safety margin after microwave ablation of stage I NSCLC with three-dimensional reconstruction technique using CT imaging.

Authors:  Peng Yan; An-Na Tong; Xiu-Li Nie; Min-Ge Ma
Journal:  BMC Med Imaging       Date:  2021-06-07       Impact factor: 1.930

8.  [Advances and Challenges of Local Thermal Ablation in Non-small Cell Lung Cancer].

Authors:  Qing Gou; Zejian Zhou; Mingfang Zhao; Xiaoming Chen; Qing Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-02-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.